Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

被引：0
|
作者：
Shanshan Hu
Yilai Wu
Jiajie Luan
Shuowen Wang
Guorong Fan
机构：
[1] Shanghai General Hospital,Department of Clinical Pharmacy
[2] Shanghai Jiao Tong University School of Medicine,Department of Pharmacy
[3] The First Affiliated Hospital of Wannan Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Cost–utility analysis; HER2-positive metastatic breast; Trastuzumab deruxtecan; Trastuzumab emtansine; Price exploring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：17933 / 17942
页数：9
相关论文
共 50 条
  • [21] Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
    Negar Pourjamal
    Narjes Yazdi
    Aleksi Halme
    Vadim Le Joncour
    Pirjo Laakkonen
    Pipsa Saharinen
    Heikki Joensuu
    Mark Barok
    Clinical & Experimental Metastasis, 2024, 41 : 91 - 102
  • [22] Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
    Pourjamal, Negar
    Yazdi, Narjes
    Halme, Aleksi
    Le Joncour, Vadim
    Laakkonen, Pirjo
    Saharinen, Pipsa
    Joensuu, Heikki
    Barok, Mark
    CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (02) : 91 - 102
  • [23] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [24] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Hegg, Roberto
    Chung, Wei-Pang
    Im, Seock-Ah
    Jacot, William
    Ganju, Vinod
    Chiu, Joanne Win Yang
    Xu, Binghe
    Hamilton, Erika
    Madhusudan, Srinivasan
    Iwata, Hiroji
    Altintas, Sevilay
    Henning, Jan-Willem
    Curigliano, Giuseppe
    Perez-Garcia, Jose Manuel
    Egorov, Anton
    Liu, Yali
    Cathcart, Jillian
    Ashfaque, Shahid
    Cortes, Javier
    CANCER RESEARCH, 2023, 83 (05)
  • [25] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [26] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [27] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
  • [28] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [29] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
    Guerin, Mathilde
    Sabatier, Renaud
    Goncalves, Anthony
    BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
  • [30] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
12345